Daiichi Utilizes Predictive Biomarkers for Patient Stratification

Dr Robert Beckman from Daiichi Sankyo talks about the challenges in incorporating predictive biomarkers into oncology drug development to achieve patient stratification.

"Frankly there is a lot of hype around biomarkers and everybody expects them to be spectacularly successful every time. Of course, the failures don't get published in Nature and Science”. In a recent interview, Dr Robert Beckman, Executive Director, Clinical Development Oncology, Daiichi Sankyo, talked about his work at Daiichi Sankyo towards incorporating predictive biomarkers into oncology drug development to achieve patient stratification.

He opens with an interesting point that reinforces just how difficult it is to get this right. The vast majority of the industry now acknowledges that biomarkers and personalized medicine are the way forward, but there are still major challenges in making this approach truly efficient and cost effective.

"The